I'm LongbridgeAI, I can summarize articles.Greenwich LifeSciences CEO and CFO Snehal Patel purchased $29,555 worth of shares on July 30, 2026, signaling confidence. This follows regulatory approvals to expand the FLAMINGO-01 breast cancer trial globally, doubling enrollment. An analyst raised the price target due to increased commercial opportunity and trial success probability, despite a -39% YTD stock decline and a 'Strong Sell' technical signal.
New insider activity at Greenwich LifeSciences ( (GLSI) ) has taken place on July 30, 2026.
Greenwich LifeSciences just saw a notable insider move as CEO and CFO Snehal Patel purchased 2,200 shares of the company’s stock in a single transaction valued at $29,555. This buy signals increased executive confidence in the company’s future, as a top leader commits personal capital to Greenwich LifeSciences at this scale.
Greenwich LifeSciences shares moved on news that regulators in the U.K., FDA, and EMA approved expanding the FLAMINGO-01 breast cancer trial to include all HLA patient types across nearly 200 sites, effectively more than doubling enrollment and broadening the potential market for GP2. An analyst raised the price target mainly because this unified global protocol and larger, statistically stronger study design significantly increase the therapy’s commercial opportunity and probability of trial success while the company maintains a manageable cash burn and explores non-dilutive funding options.
More about Greenwich LifeSciences
YTD Price Performance: -39.08%
Average Trading Volume: 159,420
Technical Sentiment Signal: Strong Sell
Current Market Cap: $197.4M